Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 8

PMID 28169345

Citations 26

Authors

Ana Sofia Carvalho

Celia Marina Cuco

Carla Lavareda

Francisco Miguel

Mafalda Ventura

Sonia Almeida

Paula Pinto

Tiago Tavares de Abreu

Luis Vaz Rodrigues

Susana Seixas

Cristina Barbara

Mikel Azkargorta

Felix Elortza

Julio Semedo

John K Field

Leonor Mota

Rune Matthiesen

Affiliations

Soon will be listed here.

Abstract

Lung cancer configures as one of the deadliest types of cancer. The future implementation of early screening methods such as exhaled breath condensate analysis and low dose computed tomography (CT) as an alternative to current chest imaging based screening will lead to an increased burden on bronchoscopy units. New approaches for improvement of diagnosis in bronchoscopy units, regarding patient management, are likely to have clinical impact in the future. Diagnostic approaches to address mortality of lung cancer include improved early detection and stratification of the cancers according to its prognosis and further response to drug treatment. In this study, we performed a detailed mass spectrometry based proteome analysis of acellular bronchoalveolar lavage (BAL) fluid samples on an observational prospective cohort consisting of 90 suspected lung cancer cases which were followed during two years. The thirteen new lung cancer cases diagnosed during the follow up time period clustered, based on liquid chromatography-mass spectrometry (LC-MS) data, with lung cancer cases at the time of BAL collection. Hundred and thirty-tree potential biomarkers were identified showing significantly differential expression when comparing lung cancer versus non-lung cancer. The regulated biomarkers showed a large overlap with biomarkers detected in tissue samples.

Citing Articles

Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer.

Zhang H, Deng D, Li S, Ren J, Huang W, Liu D Cancer Biol Med. 2024; 21(3).

PMID: 38164737 PMC: 10976328. DOI: 10.20892/j.issn.2095-3941.2023.0381.

MiR-1246b, a novel miRNA molecule of extracellular vesicles in bronchoalveolar lavage fluid, promotes nodule growth through FGF14 in patients with lung cancer.

Huang J, Ding M, Lu Y, Xu L, Zhang Y, Han S Cell Death Dis. 2023; 14(12):789.

PMID: 38040694 PMC: 10692082. DOI: 10.1038/s41419-023-06218-9.

Successful treatment with osimertinib for nonmucinous bronchioloalveolar carcinoma with massive bronchorrhea and respiratory failure: a case report and literature review.

Tong J, Wang D, Zhou Z, Deng W Transl Cancer Res. 2023; 12(2):427-433.

PMID: 36915575 PMC: 10007879. DOI: 10.21037/tcr-22-1853.

Extracellular Vesicles in Lung Cancer: Bystanders or Main Characters?.

Tine M, Biondini D, Damin M, Semenzato U, Bazzan E, Turato G Biology (Basel). 2023; 12(2).

PMID: 36829523 PMC: 9953694. DOI: 10.3390/biology12020246.

Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer.

Kalkanis A, Papadopoulos D, Testelmans D, Kopitopoulou A, Boeykens E, Wauters E Diagnostics (Basel). 2022; 12(12).

PMID: 36552956 PMC: 9776496. DOI: 10.3390/diagnostics12122949.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Hackenberg M, Matthiesen R . Annotation-Modules: a tool for finding significant combinations of multisource annotations for gene lists. Bioinformatics. 2008; 24(11):1386-93. DOI: 10.1093/bioinformatics/btn178. View

Ortea I, Rodriguez-Ariza A, Chicano-Galvez E, Arenas Vacas M, Jurado Gamez B . Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics. 2016; 138:106-14. DOI: 10.1016/j.jprot.2016.02.010. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E . Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016; 18(8):897-909. DOI: 10.1038/ncb3380. View

Vant Westeinde S, van Klaveren R . Screening and early detection of lung cancer. Cancer J. 2011; 17(1):3-10. DOI: 10.1097/PPO.0b013e3182099319. View

Schlosser A, Volkmer-Engert R . Volatile polydimethylcyclosiloxanes in the ambient laboratory air identified as source of extreme background signals in nanoelectrospray mass spectrometry. J Mass Spectrom. 2003; 38(5):523-5. DOI: 10.1002/jms.465. View

Field J, Duffy S . Lung cancer CT screening: is annual screening necessary?. Lancet Oncol. 2016; 17(5):543-4. DOI: 10.1016/S1470-2045(16)00079-6. View

Carvalho A, Molina H, Matthiesen R . New insights into functional regulation in MS-based drug profiling. Sci Rep. 2016; 6:18826. PMC: 4705526. DOI: 10.1038/srep18826. View

10.

MacMahon H, Austin J, Gamsu G, Herold C, Jett J, Naidich D . Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005; 237(2):395-400. DOI: 10.1148/radiol.2372041887. View

11.

Oumeraci T, Schmidt B, Wolf T, Zapatka M, Pich A, Brors B . Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology. Lung Cancer. 2011; 72(1):136-8. DOI: 10.1016/j.lungcan.2011.01.015. View

12.

Sun H, Xing X, Li J, Zhou F, Chen Y, He Y . Identification of gene fusions from human lung cancer mass spectrometry data. BMC Genomics. 2014; 14 Suppl 8:S5. PMC: 4042237. DOI: 10.1186/1471-2164-14-S8-S5. View

13.

Matthiesen R, Prieto G, Amorim A, Aloria K, Fullaondo A, Carvalho A . SIR: Deterministic protein inference from peptides assigned to MS data. J Proteomics. 2012; 75(13):4176-83. DOI: 10.1016/j.jprot.2012.05.010. View

14.

Lopes A, Aston K, Thompson E, Carvalho F, Goncalves J, Huang N . Human spermatogenic failure purges deleterious mutation load from the autosomes and both sex chromosomes, including the gene DMRT1. PLoS Genet. 2013; 9(3):e1003349. PMC: 3605256. DOI: 10.1371/journal.pgen.1003349. View

15.

Vachani A, Whitney D, Parsons E, Lenburg M, Ferguson J, Silvestri G . Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. Chest. 2016; 150(1):210-8. DOI: 10.1016/j.chest.2016.02.636. View

16.

Wongsurakiat P, Wongbunnate S, Dejsomritrutai W, Charoenratanakul S, Tscheikuna J, Youngchaiyud P . Diagnostic value of bronchoalveolar lavage and postbronchoscopic sputum cytology in peripheral lung cancer. Respirology. 1998; 3(2):131-7. DOI: 10.1111/j.1440-1843.1998.tb00111.x. View

17.

Vander Heiden M, Lunt S, Dayton T, Fiske B, Israelsen W, Mattaini K . Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol. 2012; 76:325-34. DOI: 10.1101/sqb.2012.76.010900. View

18.

Tenzer S, Leidinger P, Backes C, Huwer H, Hildebrandt A, Lenhof H . Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase. Oncotarget. 2016; 7(12):14857-70. PMC: 4924757. DOI: 10.18632/oncotarget.7562. View

19.

Wang S, Xiong H, Yan S, Wu N, Lu Z . Identification and Characterization of Epstein-Barr Virus Genomes in Lung Carcinoma Biopsy Samples by Next-Generation Sequencing Technology. Sci Rep. 2016; 6:26156. PMC: 4870493. DOI: 10.1038/srep26156. View

20.

Pastor M, Nogal A, Molina-Pinelo S, Melendez R, Salinas A, Gonzalez De la Pena M . Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics. 2013; 89:227-37. DOI: 10.1016/j.jprot.2013.04.037. View